# Rocket Pharmaceuticals, Inc.: financial statements, quarterly

RCKT · Nasdaq · CIK 1281895 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rckt.md) · [Financials](/companies/rckt/financials.md) · [Filings](/companies/rckt/filings.md) · [Insiders](/companies/rckt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rckt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-123459.md) | [0.0 d](/filings/0000950170-25-029002.md) | [0.0](/filings/0000950170-25-066898.md) | [0.0](/filings/0000950170-25-104996.md) | [0.0](/filings/0001193125-25-269474.md) | [0.0 d](/filings/0001193125-26-076551.md) | [0.0](/filings/0001193125-26-211873.md) | [0.0](/filings/0001193125-26-342348.md) | [0.0](/filings/0001193125-25-269474.md) | [0.0 d](/filings/0001193125-26-076551.md) | [0.0](/filings/0001193125-26-211873.md) | [0.0](/filings/0001193125-26-342348.md) |
| Research and development | $m | [46.8](/filings/0000950170-24-123459.md) | [41.7 d](/filings/0000950170-25-029002.md) | [45.2](/filings/0000950170-25-066898.md) | [46.3](/filings/0000950170-25-104996.md) | [42.3](/filings/0001193125-25-269474.md) | [37.4 d](/filings/0001193125-26-076551.md) | [35.9](/filings/0001193125-26-211873.md) | [42.7](/filings/0001193125-26-342348.md) | [34.1](/filings/0001193125-25-269474.md) | [29.3 d](/filings/0001193125-26-076551.md) | [31.5](/filings/0001193125-26-211873.md) | [29.5](/filings/0001193125-26-342348.md) |
| Operating income | $m | [(65.4)](/filings/0000950170-24-123459.md) | [(63.3) d](/filings/0000950170-25-029002.md) | [(67.4)](/filings/0000950170-25-066898.md) | [(73.7)](/filings/0000950170-25-104996.md) | [(69.4)](/filings/0001193125-25-269474.md) | [(62.7) d](/filings/0001193125-26-076551.md) | [(64.4)](/filings/0001193125-26-211873.md) | [(71.1)](/filings/0001193125-26-342348.md) | [(52.2)](/filings/0001193125-25-269474.md) | [(44.0) d](/filings/0001193125-26-076551.md) | [(48.5)](/filings/0001193125-26-211873.md) | [(46.9)](/filings/0001193125-26-342348.md) |
| Interest expense | $m | [0.5](/filings/0000950170-24-123459.md) | [0.5 d](/filings/0000950170-25-029002.md) | [0.5](/filings/0000950170-25-066898.md) | [0.5](/filings/0000950170-25-104996.md) | [0.5](/filings/0001193125-25-269474.md) | [0.5 d](/filings/0001193125-26-076551.md) | [0.5](/filings/0001193125-26-211873.md) | [0.5](/filings/0001193125-26-342348.md) | [0.5](/filings/0001193125-25-269474.md) | [0.5 d](/filings/0001193125-26-076551.md) | [0.5](/filings/0001193125-26-211873.md) | [0.5](/filings/0001193125-26-342348.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-342348.md) | not reported | not reported | not reported | [8.6](/filings/0001193125-26-342348.md) |
| Net income | $m | [(61.9)](/filings/0000950170-24-123459.md) | [(59.7) d](/filings/0000950170-25-029002.md) | [(62.1)](/filings/0001193125-25-269474.md) | [(69.6)](/filings/0001193125-25-269474.md) | [(66.7)](/filings/0001193125-25-269474.md) | [(60.3) d](/filings/0001193125-26-076551.md) | [(61.3)](/filings/0001193125-26-342348.md) | [(68.9)](/filings/0001193125-26-342348.md) | [(50.3)](/filings/0001193125-25-269474.md) | [(42.5) d](/filings/0001193125-26-076551.md) | [(47.6)](/filings/0001193125-26-342348.md) | [123](/filings/0001193125-26-342348.md) |
| Diluted EPS | $ per share | [(0.75)](/filings/0000950170-24-123459.md) | not reported | [(0.66)](/filings/0000950170-25-066898.md) | [(0.74)](/filings/0000950170-25-104996.md) | [(0.71)](/filings/0001193125-25-269474.md) | not reported | [(0.56)](/filings/0001193125-26-211873.md) | [(0.62)](/filings/0001193125-26-342348.md) | [(0.45)](/filings/0001193125-25-269474.md) | not reported | [(0.42)](/filings/0001193125-26-211873.md) | [1.08](/filings/0001193125-26-342348.md) |
| Basic EPS | $ per share | [(0.75)](/filings/0000950170-24-123459.md) | not reported | [(0.66)](/filings/0000950170-25-066898.md) | [(0.74)](/filings/0000950170-25-104996.md) | [(0.71)](/filings/0001193125-25-269474.md) | not reported | [(0.56)](/filings/0001193125-26-211873.md) | [(0.62)](/filings/0001193125-26-342348.md) | [(0.45)](/filings/0001193125-25-269474.md) | not reported | [(0.42)](/filings/0001193125-26-211873.md) | [1.09](/filings/0001193125-26-342348.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [226](/filings/0000950170-23-060339.md) | [55.9](/filings/0000950170-25-029002.md) | [35.3](/filings/0000950170-24-054465.md) | [38.6](/filings/0000950170-24-091838.md) | [65.6](/filings/0000950170-24-123459.md) | [164](/filings/0001193125-26-076551.md) | [49.8](/filings/0000950170-25-066898.md) | [32.8](/filings/0000950170-25-104996.md) | [75.9](/filings/0001193125-25-269474.md) | [77.6](/filings/0001193125-26-342348.md) | [49.6](/filings/0001193125-26-211873.md) | [225](/filings/0001193125-26-342348.md) |
| Current assets | $m | [447](/filings/0000950170-23-060339.md) | [378](/filings/0000950170-25-029002.md) | [345](/filings/0000950170-24-054465.md) | [293](/filings/0000950170-24-091838.md) | [242](/filings/0000950170-24-123459.md) | [378](/filings/0001193125-26-076551.md) | [324](/filings/0000950170-25-066898.md) | [277](/filings/0000950170-25-104996.md) | [228](/filings/0001193125-25-269474.md) | [193](/filings/0001193125-26-342348.md) | [150](/filings/0001193125-26-211873.md) | [290](/filings/0001193125-26-342348.md) |
| Total assets | $m | [599](/filings/0000950170-23-060339.md) | [566](/filings/0000950170-25-029002.md) | [499](/filings/0000950170-24-054465.md) | [446](/filings/0000950170-24-091838.md) | [394](/filings/0000950170-24-123459.md) | [528](/filings/0001193125-26-076551.md) | [471](/filings/0000950170-25-066898.md) | [421](/filings/0000950170-25-104996.md) | [368](/filings/0001193125-25-269474.md) | [330](/filings/0001193125-26-342348.md) | [285](/filings/0001193125-26-211873.md) | [423](/filings/0001193125-26-342348.md) |
| Current liabilities | $m | [33.5](/filings/0000950170-23-060339.md) | [48.5](/filings/0000950170-25-029002.md) | [33.0](/filings/0000950170-24-054465.md) | [37.6](/filings/0000950170-24-091838.md) | [40.0](/filings/0000950170-24-123459.md) | [40.7](/filings/0001193125-26-076551.md) | [35.3](/filings/0000950170-25-066898.md) | [43.4](/filings/0000950170-25-104996.md) | [31.2](/filings/0001193125-25-269474.md) | [30.2](/filings/0001193125-26-342348.md) | [24.5](/filings/0001193125-26-211873.md) | [31.3](/filings/0001193125-26-342348.md) |
| Total liabilities | $m | [57.7](/filings/0000950170-23-060339.md) | [73.8](/filings/0000950170-25-029002.md) | [57.9](/filings/0000950170-24-054465.md) | [61.8](/filings/0000950170-24-091838.md) | [63.9](/filings/0000950170-24-123459.md) | [64.5](/filings/0001193125-26-076551.md) | [58.9](/filings/0000950170-25-066898.md) | [66.8](/filings/0000950170-25-104996.md) | [54.4](/filings/0001193125-25-269474.md) | [53.2](/filings/0001193125-26-342348.md) | [47.4](/filings/0001193125-26-211873.md) | [54.3](/filings/0001193125-26-342348.md) |
| Shareholders' equity | $m | [541](/filings/0000950170-24-123459.md) | [493](/filings/0001193125-26-076551.md) | [442](/filings/0001193125-25-269474.md) | [385](/filings/0001193125-25-269474.md) | [330](/filings/0001193125-25-269474.md) | [463](/filings/0001193125-26-342348.md) | [412](/filings/0001193125-26-342348.md) | [354](/filings/0001193125-26-342348.md) | [314](/filings/0001193125-25-269474.md) | [277](/filings/0001193125-26-342348.md) | [238](/filings/0001193125-26-342348.md) | [369](/filings/0001193125-26-342348.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(57.1) d](/filings/0000950170-24-123459.md) | [(29.3) d](/filings/0000950170-25-029002.md) | [(56.9)](/filings/0000950170-25-066898.md) | [(53.8) d](/filings/0000950170-25-104996.md) | [(52.1) d](/filings/0001193125-25-269474.md) | [(46.9) d](/filings/0001193125-26-076551.md) | [(55.8)](/filings/0001193125-26-211873.md) | [(49.0) d](/filings/0001193125-26-342348.md) | [(50.4) d](/filings/0001193125-25-269474.md) | [(34.8) d](/filings/0001193125-26-076551.md) | [(45.4)](/filings/0001193125-26-211873.md) | [(39.6) d](/filings/0001193125-26-342348.md) |
| Capital expenditure | $m | [4.7 d](/filings/0000950170-24-123459.md) | [4.6 d](/filings/0000950170-25-029002.md) | [2.0](/filings/0000950170-25-066898.md) | [1.9 d](/filings/0000950170-25-104996.md) | [1.6 d](/filings/0001193125-25-269474.md) | [0.3 d](/filings/0001193125-26-076551.md) | [0.4](/filings/0001193125-26-211873.md) | [0.1 d](/filings/0001193125-26-342348.md) | [(0.1) d](/filings/0001193125-25-269474.md) | [0.1 d](/filings/0001193125-26-076551.md) | [0.1](/filings/0001193125-26-211873.md) | [0.0 d](/filings/0001193125-26-342348.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [66.2](/filings/0000950170-23-060339.md) | [79.5](/filings/0000950170-24-054465.md) | [80.5](/filings/0000950170-24-091838.md) | [82.6](/filings/0000950170-24-123459.md) | [93.5](/filings/0000950170-25-066898.md) | [93.7](/filings/0000950170-25-104996.md) | [94.2](/filings/0001193125-25-269474.md) | [110](/filings/0001193125-26-211873.md) | [111](/filings/0001193125-26-342348.md) | [112](/filings/0001193125-25-269474.md) | [112](/filings/0001193125-26-211873.md) | [115](/filings/0001193125-26-342348.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 109,774,597 at 2026-07-31, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-342348.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.